The FDA says approval for booster shots targeting new coronavirus variants would happen much more quickly than approval for the initial vaccines.
The agency is planning a rapid review process, meaning it wouldn't require the large-scale trials needed for emergency use authorization.
Pfizer and Moderna say they're already preparing for variants that would require a new booster shot to be developed.
This comes as existing vaccines have been shown to be less effective against variants coming out of South Africa and Brazil.
